RxDoctor Payments Data

Kenneth Manchon, MD

Internal Medicine · Atlantis, FLNPI 1073569398

Payments from drug & device makers

$1,452in general payments, 2019–2025

Across 76 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$212
  • AbbVie$187
  • Pfizer$175
  • Amgen$170
  • Novo Nordisk$105
  • Amarin Pharma, Inc.$78
  • plus $525 from 16 others

What the payments were for

  • Food & beverage$1,39296%
  • Education$604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,452 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$304,952
Medicare patients
830
Services billed
5,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$200,730
OzempicSemaglutide98$123,439
JardianceEmpagliflozin73$89,817
MounjaroTirzepatide50$66,538
XareltoRivaroxaban58$49,439
Tresiba Flextouch U-200Insulin Degludec12$29,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,468
LinzessLinaclotide28$22,829
JanuviaSitagliptin Phosphate15$21,648
JanumetSitagliptin Phos/Metformin Hcl17$15,791
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,942
Repatha SureclickEvolocumab13$11,839
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$9,350
Atorvastatin Calcium922$8,637
Levothyroxine Sodium770$8,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$200,730185 claims
Novo NordiskOzempic$105$123,43998 claims
Johnson & JohnsonXarelto$56$49,43958 claims
MerckJanuvia, Janumet$42$37,43832 claims
GSKTrelegy Ellipta, Anoro Ellipta$47$37,41047 claims
AbbVieLinzess, Synthroid$187$29,207113 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$16$4,60116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →